1.21 Nab-Paclitaxel in CCA, OS of PALOMA-3, Transparency, and Dr. Talal Hilal's Advice for Trainees

Plenary Session

English - November 06, 2018 17:03 - 1 hour - 79.5 MB - ★★★★★ - 722 ratings
Science Health & Fitness Medicine medicine oncology health policy Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: 1.20 Precision Oncology: Some Benefit, Mostly Hype and Mentorship with Dr. Andrae Vandross

Next Episode: 1.22 Elo-Pom-Dex, Immunotherapy Combos, Inherent Bias, and the FDA with Dr. Erick Turner

In this episode we question the conclusions of the phase II trial "Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma", review the long-term overall survival results from PALOMA-3, discuss Dr. Gyawali et al.'s paper on the need for transparency in reporting harms from cancer drugs, and interview Dr. Talal Hilal from the Scottsdale Mayo Clinic on his advice for trainees.

Nab-paclitaxel and gemcitabine: doi.org/10.1001/jamaoncol.2018.3277
Palbociclib and fulvestrant: doi.org/10.1056/NEJMoa1810527
Reporting harms: doi.org/10.1136/bmj.k4383